載入...
Profound thrombocytopenia after primary exposure to eptifibatide
Eptifibatide is a glycoprotein IIb/IIIa receptor antagonist used to reduce the incidence of ischemic events in patients with acute coronary syndromes and those undergoing percutaneous coronary intervention. A minority of patients given eptifibatide develop acute, profound thrombocytopenia (<20,00...
Na minha lista:
| Main Authors: | , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2010
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3108691/ https://ncbi.nlm.nih.gov/pubmed/21701628 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DHPS.S13239 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|